Page 18 - Service Testing News Today

By Denny Jacob Allarity Therapeutics shares rise 15%, to 69 cents, following initial results from its continuing clinical trial evaluating the efficacy of...

By Adriano Marchese Shares of NeuroSense Therapeutics were lower after it said trials for its ALS treatment met primary safety and tolerability endpoints, as...

Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.

EyePoint's stock is on track for its biggest ever one-day percentage gain in heavy volume.

The race for weight-loss drugs stepped up Monday after Roche said it would buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.

Pfizer's drug helped patients lose weight but also caused nausea and diarrhea.

'We believe an improved once-daily formulation of danuglipron could play an important role in the obesity treatment paradigm,' Pfizer says

Health-care companies rose, but not by as much as the broad market, after a major setback for one entrant in the race to launch an effective weight-loss...

By Ben Glickman Shares of Biora Therapeutics rose late Thursday after the company received clearance from the U.S. Food and Drug Administration to use its...

By Chris Wack Fortrea said in a filing to the U.S. Securities and Exchange Commission that it disputes the accuracy of statements made by Acelyrin regarding...